| 1 | Gut Microbiota in Immuno-Oncology: A Practical Guide for Medical Oncologists With a Focus on Antibiotics Stewardship | 4.4 | 24 | Citations (PDF) |
| 2 | The Microbiome and Cancer | 16.5 | 45 | Citations (PDF) |
| 3 | Androgen drives melanoma invasiveness and metastatic spread by inducing tumorigenic fucosylation | 13.7 | 23 | Citations (PDF) |
| 4 | Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity | 25.1 | 67 | Citations (PDF) |
| 5 | Jennifer A. Wargo, Nadim J. Ajami, and Carrie R. Daniel-MacDougall | 6.6 | 0 | Citations (PDF) |
| 6 | Long-Term Follow-up of Levonorgestrel Intrauterine Device for Atypical Hyperplasia and Early Endometrial Cancer Reveals Relapse Characterized by Immune Exhaustion | 6.8 | 6 | Citations (PDF) |
| 7 | Inflammation Mediated by Gut Microbiome Alterations Promotes Lung Cancer Development and an Immunosuppressed Tumor Microenvironment | 4.2 | 25 | Citations (PDF) |
| 8 | Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma | 6.8 | 34 | Citations (PDF) |
| 9 | Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration | 9.3 | 59 | Citations (PDF) |
| 10 | Microbiome influencers of checkpoint blockade–associated toxicity | 9.3 | 31 | Citations (PDF) |
| 11 | Fucosylation of HLA-DRB1 regulates CD4+ T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy | 22.5 | 48 | Citations (PDF) |
| 12 | Monitoring and Modulating Diet and Gut Microbes to Enhance Response and Reduce Toxicity to Cancer Treatment | 3.8 | 21 | Citations (PDF) |
| 13 | Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma | 4.2 | 4 | Citations (PDF) |
| 14 | Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial | 33.0 | 187 | Citations (PDF) |
| 15 | Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results | 33.0 | 75 | Citations (PDF) |
| 16 | Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance | 37.9 | 174 | Citations (PDF) |
| 17 | Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy | 70.7 | 113 | Citations (PDF) |
| 18 | Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells | 37.9 | 168 | Citations (PDF) |
| 19 | Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome | 6.8 | 20 | Citations (PDF) |
| 20 | Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC) | 2.3 | 37 | Citations (PDF) |
| 21 | Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma | 4.2 | 7 | Citations (PDF) |
| 22 | Evolution of FMT – From early clinical to standardized treatments | 1.4 | 10 | Citations (PDF) |
| 23 | Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers | 4.2 | 13 | Citations (PDF) |
| 24 | Mechanisms of immune activation and regulation: lessons from melanoma | 60.7 | 226 | Citations (PDF) |
| 25 | Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials | 3.6 | 31 | Citations (PDF) |
| 26 | Outcomes After Sphincter-Sparing Local Therapy for Anorectal Melanoma: 1989 to 2020 | 2.7 | 8 | Citations (PDF) |
| 27 | Utilization and evolving prescribing practice of opioid and non‐opioid analgesics in patients undergoing lymphadenectomy for cutaneous malignancy | 1.5 | 3 | Citations (PDF) |
| 28 | Evaluation of Plasma IL-6 in Patients with Melanoma as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker | 2.3 | 21 | Citations (PDF) |
| 29 | Glioma and the gut–brain axis: opportunities and future perspectives | 0.9 | 37 | Citations (PDF) |
| 30 | Targeting the gut and tumor microbiota in cancer | 33.0 | 448 | Citations (PDF) |
| 31 | Trust your gut when it comes to driving CARs | 7.0 | 1 | Citations (PDF) |
| 32 | Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity | 33.0 | 328 | Citations (PDF) |
| 33 | Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy | 37.9 | 113 | Citations (PDF) |
| 34 | Multi-modal molecular programs regulate melanoma cell state | 13.7 | 26 | Citations (PDF) |
| 35 | Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1) | 7.0 | 49 | Citations (PDF) |
| 36 | Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome | 33.0 | 220 | Citations (PDF) |
| 37 | The Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma | 25.1 | 147 | Citations (PDF) |
| 38 | The Microbiome in Gastrointestinal Cancers | 2.9 | 2 | Citations (PDF) |
| 39 | Neoadjuvant relatlimab and nivolumab in resectable melanoma | 37.9 | 305 | Citations (PDF) |
| 40 | Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment | 12.5 | 53 | Citations (PDF) |
| 41 | Tertiary lymphoid structures with overlapping histopathologic features of cutaneous marginal zone lymphoma during neoadjuvant cemiplimab therapy are associated with antitumor response | 1.1 | 10 | Citations (PDF) |
| 42 | Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy | 13.7 | 179 | Citations (PDF) |
| 43 | Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial | 33.0 | 562 | Citations (PDF) |
| 44 | Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC) | 33.0 | 378 | Citations (PDF) |
| 45 | Gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiation | 4.4 | 118 | Citations (PDF) |
| 46 | The microbiome and human cancer | 36.3 | 1,132 | Citations (PDF) |
| 47 | Identification of bacteria-derived HLA-bound peptides in melanoma | 37.9 | 400 | Citations (PDF) |
| 48 | A prospective study of the adaptive changes in the gut microbiome during standard-of-care chemoradiotherapy for gynecologic cancers | 2.3 | 34 | Citations (PDF) |
| 49 | Gut Microbiota and Antitumor Immunity: Potential Mechanisms for Clinical Effect | 4.2 | 54 | Citations (PDF) |
| 50 | Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era | 2.3 | 15 | Citations (PDF) |
| 51 | Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck | 6.8 | 128 | Citations (PDF) |
| 52 | Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1 | 13.7 | 29 | Citations (PDF) |
| 53 | Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade | 33.0 | 392 | Citations (PDF) |
| 54 | Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer | 6.8 | 67 | Citations (PDF) |
| 55 | Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer | 13.7 | 85 | Citations (PDF) |
| 56 | 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy | 13.7 | 193 | Citations (PDF) |
| 57 | Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironmentCell, 2021, 184, 5338-5356.e21 | 33.6 | 550 | Citations (PDF) |
| 58 | Hallmarks of response, resistance, and toxicity to immune checkpoint blockadeCell, 2021, 184, 5309-5337 | 33.6 | 1,469 | Citations (PDF) |
| 59 | Identification of MicroRNA–mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes | 3.8 | 12 | Citations (PDF) |
| 60 | Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in
Braf
-mutated melanoma | 5.4 | 11 | Citations (PDF) |
| 61 | Coenzyme A fuels T cell anti-tumor immunity | 25.2 | 97 | Citations (PDF) |
| 62 | Immune and Circulating Tumor DNA Profiling After Radiation Treatment for Oligometastatic Non-Small Cell Lung Cancer: Translational Correlatives from a Mature Randomized Phase II Trial | 1.5 | 44 | Citations (PDF) |
| 63 | Functional annotation of melanoma risk loci identifies novel susceptibility genes | 2.8 | 28 | Citations (PDF) |
| 64 | Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma | 9.9 | 35 | Citations (PDF) |
| 65 | Can we harness the microbiota to enhance the efficacy of cancer immunotherapy? | 53.8 | 72 | Citations (PDF) |
| 66 | Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells | 9.3 | 307 | Citations (PDF) |
| 67 | Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype | 4.2 | 63 | Citations (PDF) |
| 68 | The human tumor microbiome is composed of tumor type–specific intracellular bacteria | 36.3 | 2,195 | Citations (PDF) |
| 69 | Gut Microbiome Modulation Via Fecal Microbiota Transplant to Augment Immunotherapy in Patients with Melanoma or Other Cancers | 4.2 | 57 | Citations (PDF) |
| 70 | Uncovering the role of the gut microbiota in immune checkpoint blockade therapy: A mini-review | 3.1 | 19 | Citations (PDF) |
| 71 | Gut Microbiome Modulates Response to Cancer Immunotherapy | 2.1 | 62 | Citations (PDF) |
| 72 | Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma | 13.7 | 32 | Citations (PDF) |
| 73 | B cells are associated with survival and immunotherapy response in sarcoma | 37.9 | 1,754 | Citations (PDF) |
| 74 | Tertiary lymphoid structures improve immunotherapy and survival in melanoma | 37.9 | 2,080 | Citations (PDF) |
| 75 | B cells and tertiary lymphoid structures promote immunotherapy response | 37.9 | 2,399 | Citations (PDF) |
| 76 | Toxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon | 2.3 | 11 | Citations (PDF) |
| 77 | T-Cell Repertoire in Combination with T-Cell Density Predicts Clinical Outcomes in Patients with Merkel Cell Carcinoma | 2.3 | 19 | Citations (PDF) |
| 78 | Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma | 13.7 | 20 | Citations (PDF) |
| 79 | Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab | 6.8 | 193 | Citations (PDF) |
| 80 | Anti-tumour immunity induces aberrant peptide presentation in melanoma | 37.9 | 148 | Citations (PDF) |
| 81 | Comprehensive T cell repertoire characterization of non-small cell lung cancer | 13.7 | 208 | Citations (PDF) |
| 82 | Circulating Tumor Cells and Early Relapse in Node-positive Melanoma | 6.8 | 61 | Citations (PDF) |
| 83 | Spitzoid melanoma with histopathological features of
ALK
gene rearrangement exhibiting
ALK
copy number gain: a novel mechanism of
ALK
activation in spitzoid neoplasia | 1.7 | 7 | Citations (PDF) |
| 84 | Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers | 6.8 | 354 | Citations (PDF) |
| 85 | Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer OutcomesCell, 2019, 178, 795-806.e12 | 33.6 | 1,431 | Citations (PDF) |
| 86 | PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance | 23.5 | 310 | Citations (PDF) |
| 87 | Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium | 27.4 | 201 | Citations (PDF) |
| 88 | The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies | 1.5 | 23 | Citations (PDF) |
| 89 | Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities | 7.5 | 208 | Citations (PDF) |
| 90 | Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies | 7.5 | 325 | Citations (PDF) |
| 91 | Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade | 12.4 | 240 | Citations (PDF) |
| 92 | Modulating the microbiome to improve therapeutic response in cancer | 27.4 | 356 | Citations (PDF) |
| 93 | Role of Immune Response, Inflammation, and Tumor Immune Response–Related Cytokines/Chemokines in Melanoma Progression | 2.3 | 29 | Citations (PDF) |
| 94 | The cancer microbiome | 60.7 | 205 | Citations (PDF) |
| 95 | Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy | 3.8 | 29 | Citations (PDF) |
| 96 | Anti–CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers—Response | 6.8 | 178 | Citations (PDF) |
| 97 | Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer | 4.2 | 97 | Citations (PDF) |
| 98 | Gene expression profiling of lichenoid dermatitis immune‐related adverse event from immune checkpoint inhibitors reveals increased CD14+ and CD16+ monocytes driving an innate immune response | 1.1 | 39 | Citations (PDF) |
| 99 | The microbiome, cancer, and cancer therapy | 33.0 | 1,087 | Citations (PDF) |
| 100 | B7-H3 Expression in Merkel Cell Carcinoma–Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density | 6.8 | 39 | Citations (PDF) |
| 101 | Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases | 25.1 | 324 | Citations (PDF) |
| 102 | Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer | 7.5 | 317 | Citations (PDF) |
| 103 | Remodeling of the Collagen Matrix in Aging Skin Promotes Melanoma Metastasis and Affects Immune Cell Motility | 25.1 | 387 | Citations (PDF) |
| 104 | A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITFhigh/AXLlow melanoma | 2.8 | 41 | Citations (PDF) |
| 105 | Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features | 4.8 | 34 | Citations (PDF) |
| 106 | The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression | 6.8 | 90 | Citations (PDF) |
| 107 | A Preexisting Rare
PIK3CA
E545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in
NRAS
Melanoma and Is Dependent on S6K1 Signaling | 25.1 | 68 | Citations (PDF) |
| 108 | The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies | 2.3 | 50 | Citations (PDF) |
| 109 | Metastatic melanoma with balloon/histiocytoid cytomorphology after treatment with immunotherapy: A histologic mimic and diagnostic pitfall | 1.1 | 6 | Citations (PDF) |
| 110 | A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma | 5.4 | 28 | Citations (PDF) |
| 111 | Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial | 27.4 | 287 | Citations (PDF) |
| 112 | Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis | 27.4 | 637 | Citations (PDF) |
| 113 | Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients 2018, 6, | | 147 | Citations (PDF) |
| 114 | Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy | 5.4 | 63 | Citations (PDF) |
| 115 | Combination Immunotherapy Development in Melanoma | 4.4 | 47 | Citations (PDF) |
| 116 | Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis | 33.0 | 706 | Citations (PDF) |
| 117 | Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma | 33.0 | 776 | Citations (PDF) |
| 118 | Defining T Cell States Associated with Response to Checkpoint Immunotherapy in MelanomaCell, 2018, 175, 998-1013.e20 | 33.6 | 1,874 | Citations (PDF) |
| 119 | The Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer Therapy | 10.4 | 92 | Citations (PDF) |
| 120 | Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma | 25.1 | 101 | Citations (PDF) |
| 121 | Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma | 9.9 | 256 | Citations (PDF) |
| 122 | High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma | 5.4 | 28 | Citations (PDF) |
| 123 | Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy | 4.9 | 30 | Citations (PDF) |
| 124 | Linking Associations of Rare Low-Abundance Species to Their Environments by Association Networks | 3.9 | 22 | Citations (PDF) |
| 125 | Point of care assessment of melanoma tumor signaling and metastatic burden from μNMR analysis of tumor fine needle aspirates and peripheral blood | 3.6 | 10 | Citations (PDF) |
| 126 | Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance | 12.5 | 830 | Citations (PDF) |
| 127 | Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy | 33.6 | 5,078 | Citations (PDF) |
| 128 | Association between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes | 2.3 | 52 | Citations (PDF) |
| 129 | An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition | 9.3 | 88 | Citations (PDF) |
| 130 | Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma | 25.1 | 50 | Citations (PDF) |
| 131 | Gene Targeting Meets Cell-Based Therapy: Raising the Tail, or Merely a Whimper? | 6.8 | 1 | Citations (PDF) |
| 132 | Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon‐V600 mutations in cutaneous melanoma patients | 4.0 | 42 | Citations (PDF) |
| 133 | Hallmarks of response to immune checkpoint blockade | 5.5 | 225 | Citations (PDF) |
| 134 | Interaction of molecular alterations with immune response in melanoma | 4.0 | 27 | Citations (PDF) |
| 135 | Immunotherapy resistance: the answers lie ahead – not in front – of us 2017, 5, | | 17 | Citations (PDF) |
| 136 | VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer | 33.0 | 577 | Citations (PDF) |
| 137 | Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma | 4.3 | 139 | Citations (PDF) |
| 138 | Tumor-associated B-cells induce tumor heterogeneity and therapy resistance | 13.7 | 137 | Citations (PDF) |
| 139 | Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure | 7.1 | 70 | Citations (PDF) |
| 140 | TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence | 25.1 | 198 | Citations (PDF) |
| 141 | Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint BlockadeCell, 2017, 170, 1120-1133.e17 | 33.6 | 1,217 | Citations (PDF) |
| 142 | Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines | 6.3 | 84 | Citations (PDF) |
| 143 | Diverse types of dermatologic toxicities from immune checkpoint blockade therapy | 1.1 | 216 | Citations (PDF) |
| 144 | Uveal melanoma: From diagnosis to treatment and the science in between | 4.0 | 394 | Citations (PDF) |
| 145 | Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors | 2.3 | 28 | Citations (PDF) |
| 146 | Monitoring immune responses in the tumor microenvironment | 5.2 | 107 | Citations (PDF) |
| 147 | Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy | 4.2 | 60 | Citations (PDF) |
| 148 | Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor–Refractory Metastatic Melanoma | 14.3 | 47 | Citations (PDF) |
| 149 | Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma | 6.8 | 106 | Citations (PDF) |
| 150 | Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma | 1.9 | 53 | Citations (PDF) |
| 151 | Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 TherapyCell, 2016, 167, 397-404.e9 | 33.6 | 1,271 | Citations (PDF) |
| 152 | Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set | 7.1 | 111 | Citations (PDF) |
| 153 | The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia | 4.0 | 174 | Citations (PDF) |
| 154 | Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade | 25.1 | 922 | Citations (PDF) |
| 155 | Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy | 25.1 | 1,427 | Citations (PDF) |
| 156 | Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy | 33.0 | 235 | Citations (PDF) |
| 157 | Working with Human Tissues for Translational Cancer Research | 0.3 | 4 | Citations (PDF) |
| 158 | Use of clinical next‐generation sequencing to identify melanomas harboring SMARCB1 mutations | 1.1 | 12 | Citations (PDF) |
| 159 | Update on use of aldesleukin for treatment of high-risk metastatic melanoma | 5.2 | 26 | Citations (PDF) |
| 160 | Implementation of a Pan-Genomic Approach to Investigate Holobiont-Infecting Microbe Interaction: A Case Report of a Leukemic Patient with Invasive Mucormycosis | 2.3 | 56 | Citations (PDF) |
| 161 | Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy | 6.8 | 28 | Citations (PDF) |
| 162 | Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation | 6.3 | 71 | Citations (PDF) |
| 163 | The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies | 25.2 | 524 | Citations (PDF) |
| 164 | EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma | 25.1 | 115 | Citations (PDF) |
| 165 | Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy | 1.9 | 168 | Citations (PDF) |
| 166 | MITF Modulates Therapeutic Resistance through EGFR Signaling | 2.3 | 82 | Citations (PDF) |
| 167 | BRAF Inhibition Generates a Host–Tumor Niche that Mediates Therapeutic Escape | 2.3 | 88 | Citations (PDF) |
| 168 | Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma | 2.3 | 51 | Citations (PDF) |
| 169 | Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment | 2.3 | 45 | Citations (PDF) |
| 170 | Working with Human Tissues for Translational Cancer Research | 0.3 | 0 | Citations (PDF) |
| 171 | RAF Inhibitor Therapy Promotes Melanocytic Antigen Expression and Enhanced Anti-Tumor Immunity in Melanoma | 0.0 | 0 | Citations (PDF) |
| 172 | Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer | 25.1 | 86 | Citations (PDF) |
| 173 | Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1α and Oxidative Phosphorylation in Melanoma | 3.8 | 191 | Citations (PDF) |
| 174 | The Immune Microenvironment Confers Resistance to MAPK Pathway Inhibitors through Macrophage-Derived TNFα | 25.1 | 201 | Citations (PDF) |
| 175 | Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade | 4.2 | 248 | Citations (PDF) |
| 176 | A Potential Role for Immunotherapy in Thyroid Cancer by Enhancing NY-ESO-1 Cancer Antigen Expression | 4.4 | 28 | Citations (PDF) |
| 177 | A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors | 25.1 | 497 | Citations (PDF) |
| 178 | Case 21-2013 | 34.5 | 32 | Citations (PDF) |
| 179 | BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma | 6.8 | 901 | Citations (PDF) |
| 180 | The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition | 6.8 | 464 | Citations (PDF) |
| 181 | Potential role of 5-Aza-2′-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer | 1.8 | 27 | Citations (PDF) |
| 182 | BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice | 6.8 | 374 | Citations (PDF) |
| 183 | Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma | 6.8 | 287 | Citations (PDF) |
| 184 | A Landscape of Driver Mutations in Melanoma | 33.6 | 2,498 | Citations (PDF) |
| 185 | Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion | 37.9 | 1,695 | Citations (PDF) |
| 186 | RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) | 37.9 | 1,402 | Citations (PDF) |
| 187 | Ocular melanoma metastatic to the pancreas after a 28-year disease-free interval | 1.8 | 11 | Citations (PDF) |
| 188 | COT drives resistance to RAF inhibition through MAP kinase pathway reactivation | 37.9 | 1,395 | Citations (PDF) |
| 189 | Surgical Management of Melanoma | 2.2 | 19 | Citations (PDF) |
| 190 | Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression | 4.6 | 86 | Citations (PDF) |
| 191 | Errant central line placement | 3.1 | 1 | Citations (PDF) |
| 192 | Microbial signals in primary and metastatic brain tumors | 33.0 | 13 | Citations (PDF) |
| 193 | Cultivating the microbiome to enhance cancer immunotherapy | 70.7 | 0 | Citations (PDF) |
